ArticlePharmaceutics2021
Fe
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Natural Iron Oxide Nanoparticles Produced by Aquatic Magnetotactic Bacteria as Ideal Nanozymes for Nano-Guided Biosensing Platforms-A Systematic Review.Biosensors · 2025Pooled it
- Biomimetic membrane-coated metal nanoplatforms for enhanced BBB penetration and targeted glioblastoma therapy.International journal of pharmaceutics: X · 2026Review
- Recent Advances in Ferrite-Based Materials for Biomedical Applications: A Comprehensive Review.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Long-Term Biodistribution of FeInternational journal of molecular sciences · 2026Article
- Biomarker-targeted functionalized magnetic nanoparticles: synthesis and aptamer conjugation optimization toward Alzheimer's disease biosensing.Nanoscale advances · 2026Article
- Spatiotemporal cancer controlNanomedicine (London, England) · 2026Review
- Engineering polysaccharide nanoplatforms for glioblastoma theranostics: Bridging targeted therapy and advanced imaging.Theranostics · 2026Review
- Current advances in metal nanoparticle-based stimuli-responsive nanotherapies.Frontiers in chemistry · 2026Review
- Magnetic Nanoparticles: Synthesis and Applications in Life Sciences.ChemistryOpen · 2025Review
- A comprehensive modeling on thermal damage in tumor hyperthermia therapies using magneto-plasmonic nanocomposite.Scientific reports · 2025Article
- Nanomaterials engineered for photothermal therapy in neural tumors and neurodegenerative diseases: biomaterial design, clinical mechanisms and applications.Frontiers in bioengineering and biotechnology · 2025Review
- Leveraging Femtosecond Laser Ablation for Tunable Near-Infrared Optical Properties in MoSNanomaterials (Basel, Switzerland) · 2024Article
- New MoSPharmaceutics · 2024Article
- Article
- Illuminating and Radiosensitizing Tumors with 2DG-Bound Gold-Based Nanomedicine for Targeted CT Imaging and Therapy.Nanomaterials (Basel, Switzerland) · 2023Article
- Challenges and advances for glioma therapy based on inorganic nanoparticles.Materials today. Bio · 2023Review
- Biomimetic and Functional Nanomaterials for Molecular Imaging.Pharmaceutics · 2023Article
- Polydopamine Nanomaterials for Overcoming Current Challenges in Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2023Review
- Functionalized Carbon Nanoparticles as Theranostic Agents and Their Future Clinical Utility in Oncology.Bioengineering (Basel, Switzerland) · 2023Review
- CT and MRI Imaging of Theranostic Bimodal FeInternational journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 2 countries.
Funding
Abstract
In this study, we report the synthesis of gold-coated iron oxide nanoparticles capped with polyvinylpyrrolidone (Fe@Au NPs). The as-synthesized nanoparticles (NPs) exhibited good stability in aqueous media and excellent features as contrast agents (CA) for both magnetic resonance imaging (MRI) and X-ray computed tomography (CT). Additionally, due to the presence of the local surface plasmon resonances of gold, the NPs showed exploitable "light-to-heat" conversion ability in the near-infrared (NIR) region, a key attribute for effective photothermal therapies (PTT). In vitro experiments revealed biocompatibility as well as excellent efficiency in killing glioblastoma cells via PTT. The in vivo nontoxicity of the NPs was demonstrated using zebrafish embryos as an intermediate step between cells and rodent models. To warrant that an effective therapeutic dose was achieved inside the tumor, both intratumoral and intravenous routes were screened in rodent models by MRI and CT. The pharmacokinetics and biodistribution confirmed the multimodal imaging CA capabilities of the Fe@AuNPs and revealed constraints of the intravenous route for tumor targeting, dictating intratumoral administration for therapeutic applications. Finally, Fe@Au NPs were successfully used for an in vivo proof of concept of imaging-guided focused PTT against glioblastoma multiforme in a mouse model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.